en · de · es · fr · pt
selank-notes.peptides6908.com › Wiki › Mechanism And Evidence Status — 2026 Update

Mechanism And Evidence Status — 2026 Update

By Editorial Desk · published 2026-03-04 · last reviewed 2026-04-03 · Wiki

This is a working overview of BDNF, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-04-03. Anything still debated is marked as such rather than presented as settled.

Mechanism and Evidence Status

Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.

Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.

Identity and Structural Background

Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.

Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.

Selank at a glance

PropertyValueNotes
Primary route studiedIntranasalAlso examined parenterally in animal work
Reported plasma half-lifeMinutes to tens of minutesValues vary widely between reports
Main model systemsRodent behavioural and cell assaysHuman trials are few and small
Principal proposed targetsGABA-A receptor, GABA transaminaseMonoamine and neurotrophic pathways also reported
Evidence gradePreliminaryLimited independent replication

Selank Background And Chemical Identity

Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.

The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.

Related pages on this site

Analytical Methods and Handling

Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.

Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.

Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.

Proposed Mechanisms and Research Endpoints

Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.

Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.

Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.

Storage, Analysis, and Regulatory Status

Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.

Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.

Reference notes

=== Glucose detection === Paper-based microfluidic devices have been designed to monitor a wide variety of medical ailments. Glucose plays an important role in diabetes and cancer, and it can be detected through a catalytic cycle involving glucose oxidase, hydrogen peroxide, and horseradish peroxidase that initiates a reaction between glucose and a color indicator, frequently potassium iodide, on a paper-based microfluidic device. This is an example of colorimetric detection. The first paper-based microfluidic device, developed by George Whitesides' group at Harvard, was able to simultaneously detect protein as well as glucose via color-change reactions (potassium iodide reaction for glucose and tetrabromophenol blue reaction for the protein BSA). The bottom of the paper device is inserted into a sample solution prepared in-lab, and the amount of color change is observed. More recently, a paper-based microfluidic device using colorimetric detection was developed to quantify glucose in blood plasma. Blood plasma is separated from whole blood samples on a wax-printed device, where red blood cells are agglutinated by antibodies and the blood plasma is able to flow to a second compartment for the color-change reaction. Electrochemical detection has also been used in these devices. It provides greater sensitivity in quantification, whereas colorimetric detection is primarily used for qualitative assessments. Screen-printed electrodes and electrodes directly printed on filter paper have been used.

== Function == This gene encodes a protein that is a transmembrane receptor for growth hormone. Binding of growth hormone to the receptor leads to reorientation of a pre-assembled receptor dimer dimerization (the receptor may however also exist as monomers on the cell surface ) and the activation of an intra- and intercellular signal transduction pathway leading to growth. A common alternate allele of this gene, called GHRd3, lacks exon three and has been well characterized. Mutations in this gene have been associated with Laron syndrome, also known as the growth hormone insensitivity syndrome (GHIS), a disorder characterized by short stature (proportional dwarfism). Other splice variants, including one encoding a soluble form of the protein (GHRtr), have been observed but have not been thoroughly characterized. Laron mice (that is mice genetically engineered to carry defective Ghr), have a dramatic reduction in body mass (only reaching 50% of the weight of normal siblings), and also show a ~40% increase in lifespan.

=== Second allegation of domestic abuse === About six months after the ATP declined to take action against Zverev, in July 2023, allegations from a second woman became public through a court filing. The public prosecution office requested a penalty order against Zverev in a Berlin criminal court over alleged bodily harm against Brenda Patea, Zverev's ex-girlfriend and the mother of his daughter. On 2 October 2023, the court issued a summary penalty order against Zverev, which included a fine of €450,000. In Germany, summary orders can be issued, typically without a prior hearing, when a judge considers the evidence sufficient to support the accusation and a trial is not deemed necessary. Zverev lodged an objection against the order, which under German law resulted in a public trial. Patea spoke publicly for the first time about the alleged abuse on 1 November 2023 in an interview with the Süddeutsche Zeitung. She said that during a dispute in May 2020, Zverev pushed her into a wall and choked her. In January 2024, Zverev was appointed to serve on the ATP Players Advisory Council. The ATP has been criticized for allowing him to serve on the council while the domestic abuse charge is pending in a criminal court. Also in January 2024, Zverev was featured on the second season of the Netflix series Break Point in an episode focused on his comeback from injury. Netflix was criticized for ignoring both allegations of domestic abuse. One columnist argued that "Break Point promised to take viewers behind the curtain of professional tennis and reveal the personalities behind it.

The development of necrotizing myopathy after statin exposure is insufficient to make the diagnosis. Testing must first exclude other causes of myositis and necrotizing myopathy. A muscle biopsy consistent with SAAM will demonstrate muscle cell death with muscle fiber regeneration and typically has few inflammatory cells. Immunohistochemistry testing may demonstrate additional pathologic features of SAAM. Such findings include the presence of endothelial cell membrane attack complex in non-necrotic muscle fibers and MHC class I expression. Antibodies against HMG-CoA reductase occur in 94% of affected individuals. These antibodies are known to also occur in people who do not take statin medications. Conversely, these antibodies are absent in people who take statin medications but do not have myopathy. Thus, the presence of anti-HMG CoA reductase antibodies in someone who uses a statin and has myopathy strongly supports the diagnosis. CK levels increase to 10-100 times above normal (2000–20,000 IU/L) in more than 90% of cases. Electromyography (EMG) typically demonstrates a myopathic pattern of findings. Muscle swelling may be seen on MRI imaging.

Sources: en.wikipedia.org

Notes from published material

== Treatment == Treatment of GAMT deficiency focuses on restoration of depleted brain creatine with oral creatine supplementation in pharmacologic doses, and removal of toxic intermediate GAA via ornithine supplementation and arginine- or protein-restricted diet. Sodium benzoate supplementation is also sometimes used to decrease GAA levels. All patients are reported to benefit from creatine supplementation, with possible improvements or stabilization in symptoms. Seizures appear to reduce more with dietary arginine restriction and ornithine supplementation. Despite treatment, none of the patients have been reported to return to completely normal developmental level, if significant damage had taken place before treatment. Prior to the addition of GAMT deficiency to newborn screening panels, younger siblings of affected individuals may have been tested at birth and treated early. This early treatment can result in outcomes that are very close to normal.

Continuing Arab disquiet over Allied intentions also led during 1918 to the British Declaration to the Seven and the Anglo-French Declaration, the latter promising "the complete and final liberation of the peoples who have for so long been oppressed by the Turks, and the setting up of national governments and administrations deriving their authority from the free exercise of the initiative and choice of the indigenous populations". In 1919, King Hussein refused to ratify the Treaty of Versailles. After February 1920, the British ceased to pay subsidy to him. In August 1920, five days after the signing of the Treaty of Sèvres, which formally recognized the Kingdom of Hejaz, Curzon asked Cairo to procure Hussein's signature to both treaties and agreed to make a payment of £30,000 conditional on signature. Hussein declined and in 1921, stated that he could not be expected to "affix his name to a document assigning Palestine to the Zionists and Syria to foreigners." Following the 1921 Cairo Conference, Lawrence was sent to try and obtain the King's signature to a treaty as well as to Versailles and Sèvres, a £60,000 annual subsidy being proposed; this attempt also failed. During 1923, the British made one further attempt to settle outstanding issues with Hussein and once again, the attempt foundered, Hussein continued in his refusal to recognize the Balfour Declaration or any of the Mandates that he perceived as being his domain.

Black powder is thought to have been accidentally discovered by Chinese alchemists using saltpeter and sulfur as materials in their experiments to make gold or prepare an elixir of life. The Zhenyuan Miaodao Yaolue, a Taoist alchemical text from the Late Tang era, warned of a flammable mixture of saltpeter, realgar, sulfur, and honey burning the alchemists preparing it. In China, black powder was first used in fireworks for amusement and religious purposes, as well as in construction works, to blast rocks in order to open roads or waterways; no mention of it being used on the battlefield is made before the 10th century. In weapons, it was first used in incendiary projectiles such as fire arrows and grenades, later joined by the fire lance, an early firearm. The Wujing Zongyao of 1044 described formulas for Chinese black powder and listed a number of Chinese gunpowder weapons, accompanied by illustrations.

Sources: en.wikipedia.org

Further detail

== Related heterocycles == Benzimidazole, an analog with a fused benzene ring Dihydroimidazole or imidazoline, an analog where the 4,5-double bond is saturated Pyrrole, an analog with only one nitrogen atom in position 1 Oxazole, an analog with the nitrogen atom in position 1 replaced by oxygen Thiazole, an analog with the nitrogen atom in position 1 replaced by sulfur Pyrazole, an analog with two adjacent nitrogen atoms Triazoles, analogs with three nitrogen atoms

Electrical stimulation using implantable devices came into modern usage in the 1980s, and its techniques and applications have continued to develop and expand. These are methods where an operation is required to position an electrode. The stimulator, with the battery, similar to a pacemaker, may also be implanted, or may remain outside the body. In general, neuromodulation systems deliver electrical currents and typically consist of the following components: An epidural, subdural, or parenchymal electrode placed via minimally invasive needle techniques (so-called percutaneous leads) or an open surgical exposure to the target (surgical "paddle" or "grid" electrodes), or stereotactic implants for the central nervous system, and an implanted pulse generator (IPG). Depending on the distance from the electrode access point, an extension cable may also be added into the system. The IPG can have either a non-rechargeable battery needing replacement every 2–5 years (depending on stimulation parameters) or a rechargeable battery that is replenished via an external inductive charging system. Although most systems operate via delivery of a constant train of stimulation, there has recently been an emergence of so-called "feed-forward" stimulation, in which the device's activation is contingent on a physiological event, such as an epileptic seizure. In this circumstance, the device is activated and delivers a desynchronizing pulse to the cortical area that is undergoing an epileptic seizure.

Specially marked by cunning, despising their own inheritance in the hope of winning a greater, eager after both gain and dominion, given to imitation of all kinds, holding a certain mean between lavishness and greediness, that is, perhaps uniting, as they certainly did, these two seemingly opposite qualities. Their chief men were specially lavish through their desire of good report. They were, moreover, a race skillful in flattery, given to the study of eloquence, so that the very boys were orators, a race altogether unbridled unless held firmly down by the yoke of justice. They were enduring of toil, hunger, and cold whenever fortune laid it on them, given to hunting and hawking, delighting in the pleasure of horses, and of all the weapons and garb of war. Medieval Latin documents referred to them as Nortmanni, which means "men of the North". This name provides the etymological basis for the modern words "Norman" and "Normandy", with -ia (Normandia, like Neustria, Francia, etc.). After 911, this name replaced the term Neustria, which had formerly been used to describe the region that included Normandy. Today, nordmann (Norwegian pronunciation: ['nuɾmɑn]) in the Norwegian language denotes a Norwegian person. In the Swedish language the word for the Norwegian person is norrman.

Sulfur assimilation is the process by which living organisms incorporate sulfur into their biological molecules. In plants, sulfate is absorbed by the roots and then transported to the chloroplasts by the transpiration stream where the sulfur are reduced to sulfide with the help of a series of enzymatic reactions. Furthermore, the reduced sulfur is incorporated into cysteine, an amino acid that is a precursor to many other sulfur-containing compounds. In animals, sulfur assimilation occurs primarily through the diet, as animals cannot produce sulfur-containing compounds directly. Sulfur is incorporated into amino acids such as cysteine and methionine, which are used to build proteins and other important molecules.

Sources: en.wikipedia.org

Frequently asked questions

What mechanisms are proposed for Selank?

Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.

What happens to Selank after intranasal dosing?

The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.

How strong is the clinical evidence?

Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.

What is the peptide sequence of Selank?

The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.

Network